Advanced drug and cleantech projects progressed, but net loss widened to -7.1 MSEK in 2025. Delisting from Spotlight aims to attract international investors and secure 30–60 MSEK for clinical trials, with significant funding and debt repayment risks remaining.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.